中国医药科学
中國醫藥科學
중국의약과학
CHINA MEDICINE AND PHARMACY
2013年
11期
82-83
,共2页
欧阳青%林容杏%郑美爱%刘华敢%陈劲新
歐暘青%林容杏%鄭美愛%劉華敢%陳勁新
구양청%림용행%정미애%류화감%진경신
云南白药%依达拉奉%急性脑出血
雲南白藥%依達拉奉%急性腦齣血
운남백약%의체랍봉%급성뇌출혈
Yunnanbaiyao%Edaravone%Acute cerebral hemorrhage
目的观察云南白药联合依达拉奉治疗急性脑出血的临床疗效。方法将60例急性脑出血患者随机分成对照组和治疗组,每组30例,对照组给予常规治疗,治疗组在常规治疗的基础上,给予云南白药联合依达拉奉治疗,比较两组治疗前后的血肿体积,神经功能缺损评分及总有效率。结果治疗前后对比,治疗后两组的头颅CT血肿体积及神经功能缺损评分均降低(P<0.01);治疗后治疗组的血肿体积及神经功能缺损评分均明显低于对照组(P<0.05),治疗组总有效率86.7%,对照组总有效率73.3%,治疗组高于对照组,未出现严重的不良反应。结论云南白药联合依达拉奉治疗急性脑出血,可显著促进患者脑血肿吸收,改善神经功能缺损,安全有效。
目的觀察雲南白藥聯閤依達拉奉治療急性腦齣血的臨床療效。方法將60例急性腦齣血患者隨機分成對照組和治療組,每組30例,對照組給予常規治療,治療組在常規治療的基礎上,給予雲南白藥聯閤依達拉奉治療,比較兩組治療前後的血腫體積,神經功能缺損評分及總有效率。結果治療前後對比,治療後兩組的頭顱CT血腫體積及神經功能缺損評分均降低(P<0.01);治療後治療組的血腫體積及神經功能缺損評分均明顯低于對照組(P<0.05),治療組總有效率86.7%,對照組總有效率73.3%,治療組高于對照組,未齣現嚴重的不良反應。結論雲南白藥聯閤依達拉奉治療急性腦齣血,可顯著促進患者腦血腫吸收,改善神經功能缺損,安全有效。
목적관찰운남백약연합의체랍봉치료급성뇌출혈적림상료효。방법장60례급성뇌출혈환자수궤분성대조조화치료조,매조30례,대조조급여상규치료,치료조재상규치료적기출상,급여운남백약연합의체랍봉치료,비교량조치료전후적혈종체적,신경공능결손평분급총유효솔。결과치료전후대비,치료후량조적두로CT혈종체적급신경공능결손평분균강저(P<0.01);치료후치료조적혈종체적급신경공능결손평분균명현저우대조조(P<0.05),치료조총유효솔86.7%,대조조총유효솔73.3%,치료조고우대조조,미출현엄중적불량반응。결론운남백약연합의체랍봉치료급성뇌출혈,가현저촉진환자뇌혈종흡수,개선신경공능결손,안전유효。
Objective To observe the clinical efficacy on treatment of acute cerebral hemorrhage with Yunnan baiyao combined with edaravone.Methods 60 patients with acute cerebral hemorrhage were randomly divided into control group and treatment group,30 cases in each group,the control group was given conventional treatment,the treatment group was given Yunnan Baiyao combined with edaravone treatment on the basis of conventional therapy,compared the hematoma volume,neurological function deficit scores and the total efficiency in two groups before and after treatment. Results Compared before and after treatment,cranial CT hematoma volume and neurological deficit score were decreased after treatment in two groups(P<0.01);after treatment,the hematoma volume and neurogical deficit score were significantly lower than those in the control group(P<0.05),the total effectiveness in treatment group was 86.7%,the total effectiveness in control group was 73.3%,the treatment group higher than that in control group,without serious adverse reactions occuring. Conclusion Yunnanbaiyao combined with edaravone in treatment of acute cerebral hemorrhage,can significantly promote the absorption of cerebral hematoma,improve nerve function deficit,safe and effective.